Digirad Named One of San Diego's Fastest Growing Technology Companies in Deloitte's Technology Fast 50 Program
September 26 2005 - 12:00PM
Business Wire
Digirad Corporation (NASDAQ:DRAD), a leader in providing
solid-state medical imaging products and services to physician
offices, hospitals and imaging centers, announced today that is has
been named to Deloitte's Technology Fast 50 Program for San Diego,
a ranking of the 50 fastest growing technology companies in the
area by Deloitte & Touche LLP, one of the nation's leading
professional services firms. Rankings are based on the percentage
of revenue growth over five years from 2000 through 2004. "We are
honored and proud to be recognized in the 2005 San Diego Technology
Fast 50 for the third consecutive year based on our impressive
overall 5-year revenue growth rate of 863% through 2004. We believe
Digirad's growth during this period signifies the expanding role
and acceptance of solid-state nuclear medicine technology, as well
as the increasing demand and benefits of portable in-office nuclear
services for cardiology," said Chief Executive Officer Gary
Burbach. "Sustaining high revenue growth over five years is an
exceptional accomplishment. We commend Digirad for delivering on
its commitment to its technology. We are proud to honor Digirad as
a Deloitte Technology Fast 50 winner," said Tim Lovoy, partner,
Technology, Media & Telecommunications, Deloitte & Touche
LLP. To qualify for the Technology Fast 50, companies must have had
operating revenues of at least $50,000 in 2000 and $1,000,000 in
2004, must be public or private companies headquartered in North
America, and be a "technology company," defined as a company that
owns proprietary technology that contributes to a significant
portion of the company's operating revenues; or devotes a
significant proportion of revenues to the research and development
of technology. Using other companies' technology in a unique way
does not qualify. About Deloitte Deloitte refers to one or more of
Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and
their respective subsidiaries and affiliates. As a Swiss Verein
(association), neither Deloitte Touche Tohmatsu nor any of its
member firms has any liability for each other's acts or omissions.
Each of the member firms is a separate and independent legal entity
operating under the names "Deloitte", "Deloitte & Touche",
"Deloitte Touche Tohmatsu" or other related names. Services are
provided by the member firms or their subsidiaries or affiliates
and not by the Deloitte Touche Tohmatsu Verein. Deloitte &
Touche USA LLP is the US member firm of Deloitte Touche Tohmatsu.
In the US, services are provided by the subsidiaries of Deloitte
and Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting
LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP and
their subsidiaries), and not by Deloitte & Touche USA LLP.
About Digirad Digirad Corporation develops, manufactures and
markets solid-state, digital gamma cameras to hospitals, imaging
centers and physician offices. Digirad offers a comprehensive line
of solid-state nuclear gamma cameras that produce a high-quality
image for use in the detection of many medical conditions,
including cardiovascular disease. Digirad's cameras are unique as
their lightweight and compact design allows them to fit easily into
small office spaces. Digirad's wholly owned subsidiaries Digirad
Imaging Solutions and Digirad Imaging Systems offer a comprehensive
and mobile imaging leasing and services program for physicians who
wish to perform in-office nuclear cardiology procedures but do not
have the patient volume, capital or resources to justify purchasing
a gamma camera. For more information, please visit www.digirad.com.
Digirad(R), Digirad Imaging Solutions(R) and Cardius(R) are
registered trademarks of Digirad Corporation. Forward-Looking
Statements Digirad cautions that statements included in this press
release that are not a description of historical facts are
forward-looking statements. You can identify these statements by
the fact that they do not relate strictly to historical or current
facts and use words such as "anticipate," "estimate," "expect,"
"project," "intend," "plan," "believe" and other words and terms of
similar meaning in connection with a discussion of future operating
or financial performance or events. Examples of such statements
include the statement that our revenue growth from 2000 through
2004 may signify an expanding role and acceptance of solid-state
nuclear medicine technology, as well as an increasing demand and
benefits of portable in-office nuclear services for cardiology; our
long term performance; our prospects for future revenue growth; and
any plans for increasing market penetration in the portable
in-office nuclear medicine business. The inclusion of these and
other forward-looking statements should not be regarded as a
representation by Digirad that any of its plans or prospects will
be achieved, or that its past performance is any predictor of
future performance. Actual results may differ materially from those
set forth in this press release due to the risks and uncertainties
inherent in Digirad's business including, without limitation: the
degree to which Digirad's imaging systems and services will be
accepted by physicians and hospitals some of whom may experience
reliability issues or technical problems; the ability of Digirad to
effectively market, sell and distribute its imaging systems and
services given its limited capabilities in these areas; the degree
to which recent changes in customer profiles may reduce the number
of days service initiated per new contract or otherwise impact
Digirad's business; Digirad's ability to retain and attract key
executives, qualified managers, engineers and imaging
technologists; Digirad's ability to manage risks relating to
product liability, warranty claims, recalls, property damage and
personal injury with respect to its imaging systems; and other
risks detailed in Digirad's Securities and Exchange Commission
filings, including its Annual Report on Form 10-K and other reports
filed with the Securities and Exchange Commission. Given these
uncertainties, readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement and Digirad undertakes no
obligation to revise or update this press release including the
forward-looking statements contained herein to reflect events or
circumstances after the date hereof or to update the reasons actual
results could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future.
Digirad (NASDAQ:DRAD)
Historical Stock Chart
From May 2024 to Jun 2024
Digirad (NASDAQ:DRAD)
Historical Stock Chart
From Jun 2023 to Jun 2024